Institut Pasteur Shanghai Announces the Creation of its Global Biotech Accelerator Advance BioChinaBy Institut Pasteur Shanghai, PRNE
Monday, March 28, 2011
BIOVISION, LYON, France, March 29, 2011 - Institut Pasteur of Shanghai announces today the creation of its global
biotech accelerator company Advance BioChina.
Advance BioChina is an R&D-focused for-profit organization
that positions itself as the gateway to China for global biotech companies.
Advance BioChina co-invests with global biotech companies into Shanghai-based
Joint Ventures. Advance BioChina will incubate and develop up to 25 companies
over the next 5 years to help them develop innovative products for the
Chinese and global markets.
Advance BioChina's founder Institut Pasteur of Shanghai (IPS)
was established by the Chinese Academy of Sciences, Institut Pasteur and the
Shanghai Municipal Government in 2004 and is a legally independent non-profit
Ralf Altmeyer, Director General of IPS, "Biotech companies
will benefit from our experience in China, our scientific expertise and
technology platforms at Institut Pasteur Shanghai to achieve their product
China's pharma market has grown 15-20% p.a. over the last 8
years and is forecast to become the world's second largest biggest pharma
market by 2020. The healthcare and IP-law reforms in China are improving the
R&D environment and commercial perspectives for differentiated medical
Alice Dautry, President of Institut Pasteur, "Institut Pasteur
has a long history of translating its research into applications. The launch
of Advance BioChina arrives at the right time when our Asian Pasteur
institutes are developing strongly at the national and international level."
Zhu Zhiyuan, Executive Director of the Chinese Academy of
Sciences Shanghai Branch, "There is a significant unmet medical need in all
major diseases in China with huge patient pools. Advance BioChina capitalizes
on the great quality of science at IPS and its network with other life
science institutes at the Chinese Academy of Sciences".
Advance BioChina provides access to funding and full
incubation services paying special attention to secure the Intellectual
Property of its JV partners.
About Institut Pasteur Shanghai
Institut Pasteur Shanghai (IPS) is a legally non-profit
research organization established in 2004 to address health issues in China
and the Asian region. IPS creates synergies between the Institut Pasteur and
the Chinese Academy networks, leveraging all the assets of Shanghai as one of
the Asia leading business and technology hubs. IPS is engaged in basic
research in therapeutics, vaccines, diagnostics and medical devices and in a
broad range of infectious diseases programs such as hepatitis, HIV,
respiratory infections as well as virus-induced cancer. IPS counts 237 staff
with 37 PhD scientists and will grow up to 400 staff within the next 3 years.
IPS will move to its new buildings in Shanghai's Xuhui (16,000m2) and
Fengxian (8,000m2) districts in 2012.
For more information, please visit
For over 10 years, BioVision, the World Life Sciences Forum,
has been engaging key international leaders from different backgrounds in
debates on global issues involving science and society. Every other year in
Lyon, BioVision brings together government and business leaders, scholars,
policy makers and NGO directors. Participants analyze scientific
breakthroughs, pressing global challenges, discuss the most effective
solutions, and build lasting partnerships that enable them to create positive
For more information, please visit www.biovision.org/
Advance BioChina www.advancebiochina.com
Contact Media relations firstname.lastname@example.org; Hoby Rakoto,
Tel: +86-21-63-85-02-96, Email: email@example.com
Contact Media relations contactus at advancebiochina.com; Hoby Rakoto, Tel: +86-21-63-85-02-96, Email: contactus at advancebiochina.com
Tags: Biovision, France, Institut Pasteur Shanghai, Lyon, March 29